AgeneBio gets grants to advance therapeutics to slow Alzheimer's disease - Baltimore


Oct. 11, 2018 6:59 pm

AgeneBio gets grants to advance therapeutics to slow Alzheimer’s disease

The NIH grants for an expected $16 million will help the company with Phase 3 trials.

AgeneBio CEO Michela Gallagher.

(Courtesy photo)

Baltimore-based AgeneBio announced a pair of grants from the National Institutes of Health that will assist with clinical trials of a treatment to combat the progression of Alzheimer’s disease.

The awards from the NIH’s National Institute of Aging and the National Institute of Neurological Disorders and Stroke are expected to provide $16 million in funding, the company states.

The company’s work is based on the research of Dr. Michela Gallagher, who heads the Neurogenetics and Behavior Center at Johns Hopkins University and is currently serving as CEO of the company while on leave from the university. The research shows that overactivity in the hippocampus contributes to cognitive impairment. AgeneBio is developing treatments to slow Mild Cognitive Impairment due to Alzheimer’s disease. The condition causes a noticeable decline in cognitive abilities including memory, according to the Alzheimer’s Association.

According to the Mt. Washington–based company, the grants fund a Phase III clinical trial of a therapeutic to treat the condition. Dubbed the “Hope4MCI” trial, it will include a sub-study that includes imaging tools developed by Cerveau Technologies and Johns Hopkins Center for Imaging Science to track how the disease effects the brain, and the potential to slow it down.

Phase 3 trials typically precede an application to the FDA for approval to market a product.

“Previous support by NIA has already enabled us to complete study start up activities for the HOPE4MCI trial,” Sharon Rosenzweig-Lipson, AgeneBio’s Vice President of Research and Development, said in a statement. “The new grant will allow us to rapidly begin enrollment in the trial putting us one step closer to understanding the impact of hippocampal overactivity and tau pathology in this disease and to being able to treat MCI due to AD.”

Dr. Gallagher was also recently awarded the 2018 Melvin R. Goodes Prize for Excellence in Alzheimer’s Drug Discovery by the Alzheimer’s Drug Discovery Foundation, which came with a $150,000 award that is being used toward the Phase 3 trial, according to a news release.


Another grant is supporting a separate therapeutic that is designed to normalize brain functions in the early stages of Alzheimer’s.

Already a member? Sign in here
Connect with companies from the community
New call-to-action


Sysmex Inostics moves into bigger space near JHU medical campus

VoiceVibes’ speech coaching platform is now available on Zoom’s app marketplace

AKUA enters Silicon Valley logistics and supply chain accelerator



What Asymmetrik is doing to help lead healthcare’s digital transformation

Philadelphia, PA


Senior Interaction Designer

Apply Now
Baltimore, MD

Agora Financial

Sr. Frontend Developer

Apply Now
Baltimore, MD 21201

14 West

Junior Database Administrator

Apply Now

VitusVet partnership brings digital tools to 90+ animal hospitals releases data behind malicious ads

Frederick-based RoosterBio raises $15M Series B



Verizon is looking for the brightest ideas on how to use its 5G technology

Baltimore, MD


Account Executive (Baltimore)

Apply Now
Baltimore, MD

14 West

Product Operations Manager

Apply Now
Philadelphia OR Baltimore

Technically Media Editorial Intern (Fall 2019)

Apply Now

Sign-up for daily news updates from Baltimore

Do NOT follow this link or you will be banned from the site!